Low-risk colon cancer patients can reduce chemo: study

Three months of adjuvant chemotherapy can be as effective as six months for stage 3 colon cancer among patients with low-risk tumours, a study suggests.

The IDEA study, an international collaboration including Australians, pooled the results of six trials of six versus three months of adjuvant chemotherapy, involving nearly 13,000 patients with stage 3 colon cancer.

Patients were treated either with the FOLFOX regimen (flurouracil, leucovorin and oxaliplatin) or CAPOX (capecitabine and oxaliplatin), at their treating doctor’s discretion.

The hope was to find that

Latest

Trending